High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
Yang H, Kang B, Ha Y, Lee SH, Kim I, Kim H, Lee WS, Kim G, Jung S, Rha SY, Gaillard VE, Cheon J, Kim C, Chon HJ.
Yang H, et al. Among authors: lee sh, lee ws.
JHEP Rep. 2023 Jan 16;5(4):100672. doi: 10.1016/j.jhepr.2023.100672. eCollection 2023 Apr.
JHEP Rep. 2023.
PMID: 36866388
Free PMC article.